Stand out for this role — generate a tailored resume and cover letter in about a minute.
Zealand Pharma A/S is seeking a Project Coordinator to support global R&D project planning, execution, and monitoring. You will keep plans updated, track milestones, and coordinate cross-functional meetings to ensure timely, compliant results.
You will work closely with Project Leaders and stakeholders across departments to maintain documentation and governance standards. The role emphasizes proactive coordination, accurate communication, and adherence to SOPs, with involvement in governance
Does it excite you to be the coordination engine behind global R&D projects, and do you have a talent for keeping cross‑functional teams organized, informed, and on track? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague.
As Project Coordinator, you will support global project teams in the planning, execution, and monitoring of projects across Research and Development. You will keep projects moving — maintaining plans, tracking progress and risks, coordinating meetings, and ensuring documentation and communication stay accurate and compliant. Working closely with Project Leaders and cross‑functional stakeholders, you will be a central point of coordination that helps teams deliver timely, high‑quality results in line with our internal procedures and project governance standards.
You are highly organized, detail-oriented, and proactive — someone who brings order to complexity and keeps many moving parts aligned. You communicate clearly, follow through reliably, and build strong working relationships across functions. You take pride in accuracy and are motivated by helping teams deliver.
You will join the Project Management Office (PMO) and report to a Project Vice President. The role works in close partnership with Project Leaders and cross‑functional stakeholders across Research and Development, supporting projects throughout the portfolio.
We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture. Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let’s bond and be bold.
Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data‑driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late‑stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com. #LI-onsite Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to address a broad range of disease areas. We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes. In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long‑standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high‑profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease. Our strategy is to pursue global co‑development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.